Search hospitals > California > Los Angeles
David Geffen School of Medicine at UCLA
Claim this profileLos Angeles, California 90095
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in High Blood Pressure
Conducts research for Pulmonary Hypertension
Conducts research for Pulmonary Fibrosis
Conducts research for Idiopathic Pulmonary Fibrosis
232 reported clinical trials
9 medical researchers
Summary
David Geffen School of Medicine at UCLA is a medical facility located in Los Angeles, California. This center is recognized for care of Human Immunodeficiency Virus Infection, High Blood Pressure, Pulmonary Hypertension, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis and other specialties. David Geffen School of Medicine at UCLA is involved with conducting 232 clinical trials across 282 conditions. There are 9 research doctors associated with this hospital, such as Gary Schiller, MD, Perry Shieh, MD, PhD, Jaime G Deville, M.D., and Shaun Hussain.Area of expertise
1Human Immunodeficiency Virus Infection
Global LeaderARV
HIV infection positive
Stage I
2High Blood Pressure
Global LeaderTop PIs
Gary Schiller, MDUCLA Medical Center6 years of reported clinical research
Expert in Acute Myeloid Leukemia
Expert in Leukemia
30 reported clinical trials
52 drugs studied
Perry Shieh, MD, PhDDavid Geffen School of Medicine at UCLA1 year of reported clinical research
Studies Muscular Dystrophy
Studies Duchenne Muscular Dystrophy
15 reported clinical trials
16 drugs studied
Jaime G Deville, M.D.David Geffen School of Medicine at UCLA (CRS 5112)3 years of reported clinical research
Studies Human Immunodeficiency Virus Infection
Studies Coronavirus
7 reported clinical trials
11 drugs studied
Shaun HussainDavid Geffen School of Medicine at UCLA2 years of reported clinical research
Studies Syndrome
Studies Dravet Syndrome
4 reported clinical trials
3 drugs studied
Clinical Trials running at David Geffen School of Medicine at UCLA
Lymphoma
Pulmonary Arterial Hypertension
Non-Hodgkin's Lymphoma
Interstitial Lung Disease
Follicular Lymphoma
Small Cell Lung Cancer
Lung Cancer
Alpha-1 Antitrypsin Deficiency
Diffuse Large B-Cell Lymphoma
B-Cell Lymphoma
Epcoritamab Combinations
for Non-Hodgkin's Lymphoma
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLYâ„¢), either by itself or together with other therapies, when treating subjects with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied. Trial details include: * The total trial duration will be up to 6 years. * The treatment duration for each participant depends upon which arm of treatment they are assigned to receive, but will be no more than 3 years. * The visit frequency for each participant depends upon which arm of treatment they are assigned to receive, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks. * All participants will receive active drug; no one will be given placebo. Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned. Participants who receive standard treatments will have IV infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned. Arm 9 (follicular lymphoma (FL)) is still open for enrolment of new patients, while the other arms have closed their recruitment.
Recruiting3 awards Phase 1 & 26 criteria
Odronextamab + Chemotherapy
for B-Cell Lymphoma
This trial is testing a new drug called odronextamab with chemotherapy for patients with a type of lymphoma that hasn't been treated before, has come back, or hasn't responded to treatment. The study will check if this combination is safe and effective compared to the current standard treatment. Researchers will also look at side effects, how the drug behaves in the body, and its impact on daily life.
Recruiting2 awards Phase 36 criteria
Odronextamab + Lenalidomide
for Lymphoma
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before. The aim of Part 2, of the study is to assess how the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of care treatment for FL and/or MZL. Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug in combination with lenalidomide * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality of life and ability to complete routine daily activities
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at David Geffen School of Medicine at UCLA?
David Geffen School of Medicine at UCLA is a medical facility located in Los Angeles, California. This center is recognized for care of Human Immunodeficiency Virus Infection, High Blood Pressure, Pulmonary Hypertension, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis and other specialties. David Geffen School of Medicine at UCLA is involved with conducting 232 clinical trials across 282 conditions. There are 9 research doctors associated with this hospital, such as Gary Schiller, MD, Perry Shieh, MD, PhD, Jaime G Deville, M.D., and Shaun Hussain.